FDA Approves Intra-Cellular Therapies Novel Antipsychotic, CAPLYTA (lumateperone) for the Treatment of Schizophrenia in Adults

FDA Approves Intra-Cellular Therapies Novel Antipsychotic, CAPLYTA (lumateperone) for the

Treatment of Schizophrenia in Adults

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a

biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone) has been approved by the U.S. Food

and Drug Administration (FDA) for the treatment of schizophrenia in adults. The Company expects to initiate the commercial launch of CAPLYTA in late Q1 2020.

The efficacy of CAPLYTA 42 mg was demonstrated in two placebo-controlled trials, showing a statistically significant separation from placebo on the primary

endpoint, the Positive and Negative Syndrome Scale (PANSS) total score. The most common adverse reactions ( 5% and twice the rate of placebo) for the recommended dose of CAPLYTA vs placebo were

somnolence/sedation (24% vs.10%) and dry mouth (6% vs. 2%).

In pooled data from short term studies, mean changes from baseline in weight gain, fasting

glucose, triglycerides and total cholesterol were similar between CAPLYTA and placebo. The incidence of extrapyramidal symptoms was 6.7% for CAPLYTA and 6.3% for placebo.

We believe CAPLYTA provides healthcare providers a new, safe and effective treatment option to help the millions of adult patients with

schizophrenia, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. This approval represents the culmination of years of scientific research. We are especially grateful to the patients, their caregivers, and the

healthcare professionals who have contributed to the development of CAPLYTA.

Schizophrenia is a serious mental illness impacting approximately

2.4 million adults in the United States. The clinical presentation of schizophrenia is diverse. Acute episodes are characterized by psychotic symptoms, including hallucinations and delusions, often requiring hospitalization. The disease is

chronic and lifelong, often accompanied by depression and gradual deterioration of social functioning and cognitive ability. Patients with schizophrenia often discontinue treatment as a result of side effects such as weight gain and movement

Schizophrenia is a complex disease that severely impacts patients and their families, said Jeffrey A. Lieberman, M.D., Lawrence C.

Kolb Professor and Chairman of Psychiatry, Columbia University, College of Physicians and Surgeons and Director, New York State Psychiatric Institute. Effective treatment provided in a timely fashion can be game-changing for people living

with schizophrenia. The efficacy and safety profile of CAPLYTA approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia.

Please also see full Prescribing Information including Boxed Warning.

Important Safety Information

Boxed Warning: Elderly

patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.

Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone

or any components of CAPLYTA.

Warnings & Precautions: Antipsychotic drugs have been reported to cause:

Drug Interactions: Avoid concomitant use with CYP3A4 inducers and moderate or strong CYP3A4 inhibitors.

Special Populations: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal

symptoms following delivery. Breastfeeding is not recommended. Avoid use in patients with moderate or severe hepatic impairment.

Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs. placebo were somnolence/sedation (24% vs. 10%) and dry mouth (6% vs. 2%).

About CAPLYTA (lumateperone)

CAPLYTA is an oral, once

daily medicine approved for the treatment of schizophrenia of adults (42mg/day).

The mechanism of action of CAPLYTA in the treatment of schizophrenia is

unknown. However, the efficacy of CAPLYTA could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2

CAPLYTA is being developed for the treatment of bipolar depression, behavioral disturbances in patients with

dementia, including Alzheimer s disease, depression and other neuropsychiatric and neurological disorders. CAPLYTA has not been demonstrated to be safe and effective in these other areas. CAPLYTA was approved for the treatment of schizophrenia

in adults by the U.S. Food and Drug Administration in December 2019.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including

Parkinson s and Alzheimer s disease. The Company s first product, CAPLYTA, has received FDA approval for the treatment of schizophrenia in adults and is in development for the treatment of bipolar depression, behavioral disturbances

in patients with dementia, including Alzheimer s disease, depression and other neuropsychiatric and neurological disorders. Intra-Cellular Therapies is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry

platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company s PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with

Parkinson s disease and for the treatment of heart failure.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks

and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding,

among other things, the initiation of the commercial launch of CAPLYTA, including the timing thereof, our belief that CAPLYTA provides healthcare providers a new, safe and effective treatment option to help the millions of adult patients with

schizophrenia, our estimates of the number of adults in the United States impacted by schizophrenia, the safety and efficacy of CAPLYTA and our other product candidates; the potential for CAPLYTA to benefit patients suffering from a range of

neuropsychiatric and neurodegenerative diseases and development efforts and plans under the caption About Intra-Cellular Therapies. All such forward-looking statements are based on management s present expectations and are subject

to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited

to the following: there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in launching or commercializing CAPLYTA; whether CAPLYTA receives adequate reimbursement from third-party

payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indication; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results

achieved in CAPLYTA in the treatment of schizophrenia once we have launched the product may be different than observed in clinical trials, and may vary among patients; risks associated with our current and planned clinical trials; we may encounter

unexpected safety or tolerability issues with CAPLYTA following commercial launch for the treatment of schizophrenia or in ongoing or future trials and other development activities; our other product candidates may not be successful or may take

longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the

regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the

Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Intra-Cellular Therapies, Inc.

Vice President, Corporate Communications and Investor Relations

Burns McClellan, Inc.

Corporate Media Relations W2Owcg

Source: Intra-Cellular Therapies, Inc.